| Authors: |
Plummer R; Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom. Electronic address: Ruth.Plummer@newcastle.ac.uk., Dean E; The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: Emma.Dean@doctors.org.uk., Arkenau HT; Sarah Cannon Research Institute, London, United Kingdom. Electronic address: Tobias.Arkenau@hcahealthcare.co.uk., Redfern C; Sharp Healthcare, San Diego, CA, United States., Spira AI; Virginia Cancer Specialists Research Institute and US Oncology Research, Fairfax, VA, United States., Melear JM; Texas Oncology, Austin, TX, United States. Electronic address: Jason.Melear@usoncology.com., Chung KY; Prisma Health, Greenville, SC, United States. Electronic address: Ki.Chung@prismahealth.org., Ferrer-Playan J; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany., Goddemeier T; Merck Healthcare KGaA, Darmstadt, Germany., Locatelli G; Merck Healthcare KGaA, Darmstadt, Germany., Dong J; EMD Serono Research & Development Institute, Inc., Billerica, MA, United States., Fleuranceau-Morel P; EMD Serono Research & Development Institute, Inc., Billerica, MA, United States., Diaz-Padilla I; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany., Shapiro GI; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States. Electronic address: Geoffrey_Shapiro@dfci.harvard.edu. |
